What this is
- How it works
- How it works isn't classified yet
- Tested for
- HER2-positive Solid Tumors
- Main trialPhase 1
- “This Clinical trial is being done to understand how food and a common stomach-acid reducing medicine (called a proton pump inhibitor-PPI) affect how the body absorbs a new drug, VRN101099, in healthy adults. Researchers will measure how much of the drug gets into the bloodstream and how fast it gets there in each situation. This will help identify the most effective way for future patients to use VRN101099 in the treatment of solid tumors and cancers. The main questions it aims to answer is: 1. Does food or a PPI change how the body absorbs a single dose of VRN101099? 2. Is a single dose…”In the company’s words, NCT07550946 on ClinicalTrials.gov
Other drugs for HER2-positive Solid Tumors
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up1
- 1 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovCompletion date moved: 2026-05-01 to 2027-03-01 · ClinicalTrials.gov NCT06806982
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Sep 2026 | Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants | |
| Phase 1Recruiting | 1 Mar 2027 | A Study of VRN101099 in Patients With HER2-Positive Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026